ÂÜÀòÂÒÂ×

Dr. Sloan Lancaster joined NGM in June 2022, bringing over 25 years of pharmaceutical and biotechnology experience across all phases of drug development, with a focus on early phase exploratory medicine and clinical development in autoimmune and immune oncology across drug modalities. Prior to joining NGM, she most recently served as the Vice President, Program Management at Immunovant and the Vice President, Program Team Leadership at Calico. She began her pharmaceutical career at Eli Lilly where she was a Research Advisor in the Therapeutic Antibody discovery organization, subsequently spent over a dozen years leading clinical programs as a Senior Advisor and Program Leader at Lilly Chorus, and then was the Head of Exploratory Medicine and Clinical Pharmacology over Lilly’s Immunology and Oncology portfolios. She has strong drug development and program leadership skills and has delivered key data packages for compounds across many therapeutic areas and indications, as well as multiple drug modalities.

Joanne received her BSc in Immunology from the University of Glasgow, her PhD in Immunology from Washington University St. Louis, and did a post-doctoral fellowship at the NIH. She is a current member of CHIEF, a private network focused on women

executive leaders.